Lowest-Rated StocksLowest-RatedNYSE:NVS Novartis (NVS) Stock Price, News & Analysis $109.15 -0.20 (-0.18%) Closing price 03:59 PM EasternExtended Trading$109.00 -0.15 (-0.14%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Novartis Stock (NYSE:NVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novartis alerts:Sign Up Key Stats Today's Range$108.84▼$109.8850-Day Range$96.77▼$109.8452-Week Range$92.35▼$120.92Volume1.76 million shsAverage Volume1.95 million shsMarket Capitalization$223.10 billionP/E Ratio18.56Dividend Yield2.23%Price Target$123.38Consensus RatingReduce Company OverviewNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More… Novartis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreNVS MarketRank™: Novartis scored higher than 76% of companies evaluated by MarketBeat, and ranked 261st out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingNovartis has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on 1 buy rating, 6 hold ratings, and 3 sell ratings.Amount of Analyst CoverageNovartis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novartis' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.26% Earnings GrowthEarnings for Novartis are expected to grow by 4.26% in the coming year, from $8.45 to $8.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 18.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 18.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.65.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.70. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 5.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.21% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently decreased by 7.69%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovartis pays a meaningful dividend of 2.27%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 41.33%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 27.58% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.21% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently decreased by 7.69%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.19 News SentimentNovartis has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Novartis this week, compared to 13 articles on an average week.Search InterestOnly 10 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows10 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address NVS Stock News HeadlinesNovartis AG (NVS): Among the Cheap Pharmaceutical Stocks to Buy According to AnalystsFebruary 23 at 1:39 AM | insidermonkey.comNovartis AG (NVS): Among the Cheap Pharmaceutical Stocks to Buy According to AnalystsFebruary 22 at 11:54 PM | msn.comWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."February 24, 2025 | Brownstone Research (Ad)3 Gene Therapy Stocks With Game-Changing PotentialFebruary 21 at 3:17 PM | stocknews.comNovartis AG (NVS): Among the Best Global Stocks to Buy According to Hedge FundsFebruary 20, 2025 | msn.comNovartis: Strong Execution With A P/E DiscountFebruary 16, 2025 | seekingalpha.comNovartis (NYSE:NVS) Coverage Initiated at Morgan StanleyFebruary 15, 2025 | americanbankingnews.comNovartis: Just What The Doctor OrderedFebruary 14, 2025 | seekingalpha.comSee More Headlines NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $97.31 at the beginning of 2025. Since then, NVS stock has increased by 12.2% and is now trading at $109.15. View the best growth stocks for 2025 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) posted its quarterly earnings results on Friday, January, 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a trailing twelve-month return on equity of 37.24% and a net margin of 23.56%. Does Novartis have any subsidiaries? Novartis subsidiaries include these companies: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more. Who are Novartis' major shareholders? Top institutional shareholders of Novartis include Dodge & Cox (0.60%), Primecap Management Co. CA (0.54%), Dimensional Fund Advisors LP (0.40%) and Loomis Sayles & Co. L P (0.27%). How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK). Company Calendar Last Earnings1/31/2025Today2/24/2025Next Earnings (Estimated)4/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVS CUSIPN/A CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees75,883Year Founded1996Price Target and Rating Average Stock Price Target$123.38 High Stock Price Target$130.00 Low Stock Price Target$120.00 Potential Upside/Downside+12.5%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.88 Trailing P/E Ratio18.64 Forward P/E Ratio12.97 P/E Growth1.7Net Income$11.94 billion Net Margins23.56% Pretax Margin26.37% Return on Equity37.24% Return on Assets15.85% Debt Debt-to-Equity Ratio0.48 Current Ratio1.04 Quick Ratio0.84 Sales & Book Value Annual Sales$51.72 billion Price / Sales4.33 Cash Flow$10.93 per share Price / Cash Flow10.03 Book Value$21.59 per share Price / Book5.08Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$224.09 billion OptionableOptionable Beta0.58 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NYSE:NVS) was last updated on 2/24/2025 by MarketBeat.com Staff From Our PartnersMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in FebruaryTrump’s World Liberty Bought $1M of THIS Coin Early investors could reap HUGE benefits…Crypto 101 Media | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryA little-known IRS loophole has been gaining serious attention... If you have a retirement account, you can...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.